Projects funded by the NCN


Information on the principal investigator and host institution

Information of the project and the call

Keywords

Equipment

Delete all

Search results

14 projects found matching your search criteria :

  1. Inhibition of p21-Activated Kinase (PAK) as a new molecular target in the treatment of chronic myeloid leukemia (CML)

    Call: OPUS 6 , Panel: NZ7

    Principal investigator: dr hab. Sylwia Flis

    Narodowy Instytut Leków

  2. Mechanism regulating vitamin D analog cooperation with cytostatics and tyrosine kinase inhibitors in non-small cell lung...

    Call: PRELUDIUM 5 , Panel: NZ4

    Principal investigator: dr Ewa Maj

    Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda PAN

  3. Novel aspects of the mechanisms of vascular toxicity of tyrosine kinase inhibitors: studies on their proinflammatory act...

    Call: OPUS 26 , Panel: NZ5

    Principal investigator: dr Tomasz Prajsnar

    Uniwersytet Jagielloński, Wydział Biologii

  4. Investigating the mechanisms of CD20 downregulation triggered by tyrosine kinase inhibitors in Philadelphia chromosome-p...

    Call: PRELUDIUM 22 , Panel: NZ5

    Principal investigator: Krzysztof Domka

    Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego Polskiej Akademii Nauk

  5. Effects of tyrosine kinase inhibitors on Syk pathway in eNOS-based platelet subpopulations and on endothelial barrier in...

    Call: POLONEZ BIS 3 , Panel: NZ7

    Principal investigator: dr hab. Aneta Radziwon-Balicka

    Uniwersytet Jagielloński, Jagiellońskie Centrum Rozwoju Leków (JCET)

  6. New strategies in the treatment of non-small cell lung cancer based on silk nanocarriers targeting tumor vascularization

    Call: SONATA 17 , Panel: NZ7

    Principal investigator: dr Anna Florczak

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

  7. RE-SENSE: Dual-loaded lipid nanoparticles to overcome the resistance of non-small cell lung cancer cells to personalized...

    Call: PRELUDIUM 20 , Panel: NZ7

    Principal investigator: Mikołaj Czajkowski

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

  8. Iron chelators as tyrosine kinase inhibitors - a new strategy for the treatment of glioblastoma multiforme

    Call: PRELUDIUM BIS 2 , Panel: NZ5

    Principal investigator: dr hab. Anna Mrozek-Wilczkiewicz

    Uniwersytet Śląski w Katowicach, Wydział Nauk Ścisłych i Technicznych

  9. A novel approach based on the optimized multidrug combination for glioblastoma treatment.

    Call: SONATA 16 , Panel: NZ7

    Principal investigator: dr Małgorzata Kucińska

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

  10. Comparative evaluation of effects of tyrosine kinase inhibitors (TKIs) on endothelial function in vivo in mice

    Call: PRELUDIUM 17 , Panel: NZ5

    Principal investigator: Brygida Marczyk

    Uniwersytet Jagielloński, Jagiellońskie Centrum Rozwoju Leków (JCET)

  11. Insights into biological activity and mechanism of action of novel styrylquinazoline derivatives as tyrosine kinase inhi...

    Call: PRELUDIUM 12 , Panel: NZ7

    Principal investigator: Katarzyna Malarz

    Uniwersytet Śląski w Katowicach, Wydział Matematyki, Fizyki i Chemii

  12. Analysis of the effectiveness of anticancer activity of tyrosine kinase inhibitors combined with nanoparticles in in vit...

    Call: SONATA 11 , Panel: ST4

    Principal investigator: dr Natalia Piergies

    Instytut Fizyki Jądrowej im. Henryka Niewodniczańskiego Polskiej Akademii Nauk

  13. New MOF compounds as degradable nanocontainers of tyrosine kinases inhibitors in novel anti-cancer therapy

    Call: OPUS 9 , Panel: ST5

    Principal investigator: prof. Artur Terzyk

    Uniwersytet Mikołaja Kopernika, Wydział Chemii

  14. Protein and gene expression analysis in the course of renal cancer stem-like cells' primary resistance to sorafenib in h...

    Call: PRELUDIUM 9 , Panel: NZ5

    Principal investigator: Zofia Bielecka

    Wojskowy Instytut Medyczny